Form 4: Acurx Pharmaceuticals Director Jack H. Dean Acquires 12,000 Stock Options

Director Jack H. Dean acquired 12,000 stock options in Acurx Pharmaceuticals on June 17, 2024, related to his board service.

Summary

• Jack H. Dean, a director of Acurx Pharmaceuticals, acquired 12,000 stock options on June 17, 2024.
• The options have an exercise price of $2.38.
• These options were granted as part of the Issuer's Director Compensation Policy.
• The shares subject to the options will vest on June 17, 2025.
• Following the transaction, Mr. Dean directly owns 12,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants to a director, which is neither particularly positive nor negative on its own.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the compensation and ownership structure of the company's leadership.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it indicates a director's increased stake in the company's success.

Key Dates